Janux Therapeutics, Inc. (NASDAQ:JANX) Stock Holdings Lifted by New York State Common Retirement Fund

New York State Common Retirement Fund lifted its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 84.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,964 shares of the company’s stock after acquiring an additional 7,318 shares during the quarter. New York State Common Retirement Fund’s holdings in Janux Therapeutics were worth $855,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. Plato Investment Management Ltd increased its stake in Janux Therapeutics by 18.7% in the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after purchasing an additional 187 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Janux Therapeutics by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after acquiring an additional 339 shares in the last quarter. Avanza Fonder AB purchased a new position in shares of Janux Therapeutics in the fourth quarter worth approximately $139,000. Chicago Capital LLC acquired a new stake in shares of Janux Therapeutics during the fourth quarter valued at approximately $230,000. Finally, Chicago Partners Investment Group LLC purchased a new stake in shares of Janux Therapeutics in the 3rd quarter valued at approximately $239,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Janux Therapeutics Stock Performance

Janux Therapeutics stock opened at $31.83 on Tuesday. Janux Therapeutics, Inc. has a 52 week low of $31.36 and a 52 week high of $71.71. The stock has a market capitalization of $1.67 billion, a P/E ratio of -27.20 and a beta of 3.16. The stock has a 50-day simple moving average of $43.25 and a 200 day simple moving average of $47.86.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Research analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Insider Transactions at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $42.29, for a total transaction of $140,994.86. Following the completion of the sale, the insider now owns 82,139 shares in the company, valued at $3,473,658.31. The trade was a 3.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO David Alan Campbell sold 5,000 shares of Janux Therapeutics stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $60.00, for a total transaction of $300,000.00. Following the completion of the sale, the chief executive officer now owns 293,054 shares of the company’s stock, valued at approximately $17,583,240. The trade was a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 46,668 shares of company stock worth $2,577,515 over the last quarter. Company insiders own 29.40% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $200.00 price target on shares of Janux Therapeutics in a report on Wednesday, December 11th. Leerink Partnrs raised shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, November 22nd. Stifel Nicolaus upped their price target on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. Lifesci Capital upgraded Janux Therapeutics to a “strong-buy” rating in a report on Friday, December 27th. Finally, HC Wainwright restated a “buy” rating and issued a $70.00 target price on shares of Janux Therapeutics in a research note on Monday. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $88.00.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.